Minesh P. Mehta

Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA.

The American Society for Radiation Oncology is a professional association that operates in the field of radiation oncology. The non-profit company is based in Fairfax, VA. The CEO of the company is Laura I. Thevenot.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.

Maryland Proton Treatment Center LLC provides advanced cancer treatment options using proton therapy. The private company is based in Maryland. Proton therapy is a method of fighting cancer with protons, which decreases the chances of secondary cancers by up to. By using this treatment, patients can quickly return to doing what they love the most. Leigh T. Howe has been the CEO of the American company since 2018.

Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA.